

ASX Release

EMvision Medical Devices Ltd
ACN 620 388 230
Level 10, 12 Creek Street,
Brisbane Qld 4000
02 8667 5337
contact@emvision.com.au

EMV SECURES STRATEGIC AGREEMENT WITH KEYSIGHT TECHNOLOGIES (NYSE:KEYS)

Highlights:

- EMVision will receive exclusivity in the field of neuroimaging for the supply of the “fast sweep” feature in the VNA, which are core to the sensors that are being used inside EMVision’s portable brain scanner.
- The “fast sweep” feature in the VNA enables high fidelity imaging, and due to the speed of data capture, the measurement of cerebral blood flow via EMVision’s proprietary “pulsatility” technique under development. This exclusivity is anticipated to offer EMVision a substantial competitive advantage.
- The VNA is a custom solution developed by Keysight in collaboration with EMVision. The VNA is a high performance, lower component count, miniaturised module responsible for accurate signal measurement. The custom VNA represents a strategic investment by Keysight into the electromagnetic imaging sector.
- The VNA has enabled the EMVision device to be further miniaturised, making it ideal for environments — like ICUs and, in the future, ambulances — where space is at a premium. The integrated VNA also eliminates the need for expensive cabling, lowers the component count which further optimizes product margins whilst improving performance and ease of use.

EMVision Medical Devices Limited (ASX:EMV) (“EMVision” or the “Company”), a medical device company focused on the development and commercialisation of medical imaging technology, is pleased to announce that it has entered into a strategic Original Equipment Manufacturer (OEM) Agreement with Keysight Technologies Australia Pty Ltd (with its parent company being NYSE:KEYS) (“Keysight”).

Keysight is the world leader in radiofrequency (RF) test and measurement technology. Keysight customers span the worldwide communications ecosystem in 5G/6G, aerospace, defence, automotive and now healthcare end markets. While Keysight is not a medical device manufacturer, Keysight has the strongest portfolio of Vector Network Analysers (VNA), which are core to the sensors that are being used inside EMVision’s portable brain scanner.

In April 2019, EMVision and Keysight entered into a strategic collaboration to develop the custom healthcare-focused VNA solutions that are the subject of this Agreement. EMVision will receive exclusive supply of the “fast sweep” feature in the fully validated VNA, in the field of neuroimaging, during the term of the Agreement (including any period that the Agreement is renewed by both parties) subject to EMVision fulfilling annual product volume forecast commitments. The VNA volume commitment in the 12-month period is to supply the VNA units for the planned clinical trials. The Agreement is for a 12-month period and can be renewed prior to expiry with Agreement by both parties. The Agreement sets out pricing for the supply of VNA units in the initial term. The financial impact to the Company in the initial 12-month term is not considered material. EMVision will benefit from Keysight’s technical support expertise globally. No other consideration is payable. The Agreement may be terminated by either party, for cause, unless the breach is cured within 30 days.

The VNA has enabled the EMVision device to be further miniaturised, making it ideal for environments — like ICUs and, in the future, ambulances — where space is at a premium. The integrated VNA also eliminates the need for expensive cabling, lowers the component count which further optimizes product margins whilst improving performance and ease of use. This Agreement lays the foundation for an ongoing partnership as EMVision realizes its product, clinical and commercialisation goals.

"As a technology leader, Keysight is committed to working with industry experts like EMVision to drive breakthroughs in emerging medical technologies. Combining Keysight's test and measurement expertise and best-in-class solutions with EMVision's clinical product development expertise is anticipated to revolutionize emergency stroke diagnosis and treatment," said Huei Sin Ee, Senior Vice President of Keysight Technologies and President of Keysight's Electronic Industrial Solutions Group. "This strategic Agreement between our companies is a mark of our commitment to create a safe and healthier world, and we look forward to deepening our partnership with EMVision to fulfill this vision."

"We are pleased to partner with EMVision to contribute to the development of the new generation of portable brain scanners that will help transform point-of-care services," said Boon Juan Tan, Vice President and General Manager of General Electronics Measurement Solutions at Keysight Technologies. "This world's first portable brain imaging solution is enabled by the game-changing 'fast sweep' technology, which provides real-time diagnosis within the golden hour to save lives."

EMVision CEO, Dr Ron Weinberger, commented "the collaboration with Keysight has been first class. This Agreement recognises the roles that both parties have played in the development of the bespoke VNA over a period of 3 years. I would like to thank the Keysight team for their concerted work in developing a best-of-breed solution for EMVision and look forward to the commercial phase of our relationship".



As per the Agreement, EMVision is granted exclusivity in the field of neuroimaging for the supply of Keysight's "fast sweep" feature in the Vector Network Analysers (VNA), which feature is core to the sensors used inside EMVision's portable brain scanner. The bespoke VNA is a high-performance, lower component count unit, enabling the EMVision device to be miniaturised, making it ideal for environments — like ICUs and, in the future, ambulances — where space is at a premium. The integrated VNA also eliminates the need for expensive cabling, lowers the component count which further optimizes product margins whilst improving performance and ease of use.

Authorised for release by the Board of the Company.

[ENDS]

For further information, media or investor enquiries, please contact:

Andrew Keys
Investor Relations
+61 400 400 380
Andrew.keys@keysthomas.com

Sling & Stone
Media and Communications
emvision@slingstone.com
02 8073 5390

Scott Kirkland
Executive Director
+61 2 8667 5337
skirkland@emvision.com.au

About Keysight Technologies

Keysight delivers advanced design and validation solutions that help accelerate innovation to connect and secure the world. Keysight's dedication to speed and precision extends to software-driven insights and analytics that bring tomorrow's technology products to market faster across the development lifecycle, in design simulation, prototype validation, automated software testing, manufacturing analysis, and network performance optimization and visibility in enterprise, service provider and cloud environments. Our customers span the worldwide communications and industrial ecosystems, aerospace and defense, automotive, energy, semiconductor and general electronics markets. Keysight generated revenues of \$4.9B in fiscal year 2021. For more information about Keysight Technologies (NYSE: KEYS), visit us at www.keysight.com.

About EMVision Medical Devices

EMVision Medical Devices Limited is focused on the development and commercialisation of medical imaging technology. The Company is developing and seeking to commercialise a potentially cost effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications. The technology is the result of over 10 years of development by researchers at the University of Queensland. The team of approximately 20 researchers is led by co-inventor Professor Amin Abbosh, who is considered a global leader in electromagnetic microwave imaging. EMVision's Chief Scientific Officer is Professor Stuart Crozier, who is a co-inventor and is globally renowned for creating technology central to most MRI machines manufactured since 1997. EMVision's CEO, Dr Ron Weinberger, is the Former Executive Director and CEO of Nanosonics' (ASX:NAN), a \$2 billion market cap healthcare company. Dr Weinberger has over 25-years' experience developing and commercialising medical devices. During his time at Nanosonics, Dr Weinberger co-developed the company's platform technology and launched their breakthrough product 'Tropon' globally, which would go on to become the gold standard for infection prevention. Dr Weinberger was instrumental in transforming Nanosonics from a research and development company to one of Australia's leading medical device commercialisation success stories.

Forward-looking Statements

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking

statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.